Device Peripheral Intervention

Check-Flo

Payments companies reported to CMS as associated with Check-Flo. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$368Kassociated payments (2023-2025)

3clinicians with associated payments

1company reporting

By year

2025 $368K

Payments reported as associated with Check-Flo, per program year, as reported to CMS.

Who makes it

Cook Incorporated $368K associated with Check-Flo (2023-2025)

Specialties most often involved

Interventional Cardiology $233K

Diagnostic Radiology $128K

Vascular & Interventional Radiology $7,240

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Check-Flo

These are the largest totals companies reported as associated with Check-Flo. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

Clinician	Location	Specialty	Associated payments (2023-2025)
Gary Ansel	Columbus, OH	Interventional Cardiology	$232,918.74
Peter Balkin	Honolulu, HI	Diagnostic Radiology	$128,311.58
Lawrence Hofmann	Stanford, CA	Vascular & Interventional Radiology	$7,239.97

Prescribed Check-Flo?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

What this means, and what it doesn't

These payments are legal and common. Drug and device makers routinely pay for meals at educational events, consulting, speaking, travel, and research. Companies are required by federal law to report them; that's why this data exists.
A payment is not evidence of wrongdoing. Most clinicians who accept industry payments provide excellent care. Research payments in particular often reflect participation in clinical trials.
Context beats raw numbers. A few hundred dollars in sandwiches over several years is typical. What's worth understanding is scale, source, and purpose, which is what this page shows.
The data comes from companies, not doctors. Figures are "as reported to CMS" by the paying companies. Clinicians can dispute records through CMS's official process.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.